Biomedica Immunoassays

575 €

Contact us!

ENDOSTATIN ELISA

Wide dynamic range.

PRODUCT DETAILS

Assay characteristics:

Cat.No.: BI-20742
Method: Sandwich ELISA, HRP/TMB, 12x8-well strips
Sample type:Urine, serum, plasma (EDTA, heparin, citrate)
Standard range:0-800 pmol/l (7 standards)
Standard points:0/25/50/100/200/400/800 pmol/l
Control:2 controls
Sample size:10-20 µl / well
Incubation time:3 h / 1 h / 30 min
Unit conversion:1 pg/ml = 0.05 pmol/l (MW: 20 kDa)

Sensitivity:
LOD: 4 pmol/l (0 pmol/l + 3 SD), LLOQ: 3 pmol/l

Precision:
Intra-assay (n=5) ≤ 6%, Inter-assay (n=16) ≤ 5%

Spike/Recovery:
The mean recovery of recombinant Endostatin in serum and citrate plasma is 95% and 91%, respectively.
The mean recovery of recombinant Endostatin in heparin plasma and EDTA plasma is 96% and 92%, respectively.  

Dilution linearity:
The mean dilution linearity of endogenous Endostatin in serum sampes is:
Mean for 1+29 dilution = 119%
Mean for 1+59 dilution = 120%
Mean for 1+119 dilution = 116%. 

Cross reactivity:
This assay recognizes endogenous and recombinant human Endostatin. There is no cross reactivitiy with other species. There is no cross reactivity with human recombinant Collagen Type XV (COL15).

Values from apparently healthy individuals:
Median (serum, n=59): 5.1 nmol/l.
It is recommended to establish the normal range for each laboratory.   

Principle of the assay: 



Manual ELISAs - easily adaptable for automation! 

Back to top

INSTRUCTIONS FOR USE

Click following link for: 

BI-20742 Endostatin ELISA IFU

Biomedica Analytical Service Quotation Form

Back to top

VALIDATION DATA

Click following link for assay validation data (S/R, dilution linearity, precision, ...).

BI-20742 - Endostatin ELISA Validation Data

Back to top

ADDITIONAL INFORMATION

Endostatin, a 20-kDa C-terminal proteolytic fragment of collagen XVIII, is an endogenous angiogenesis inhibitor localized in the vascular basement membrane in various organs (http://www.uniprot.org/uniprot/P39060). The biological functions of the endostatin-network involve SPARC, thrombospondin-1, glycosaminoglycans, collagens, and integrins.

Endostatin is expressed during the progression of renal fibrosis in tubular cells of injured tissue. In renal microvascular disease, observed in late stages of patients with chronic kidney disease, increased endostatin levels are possibly the consequence of enhanced extracellular matrix degradation. Thus endostatin may become an important marker for progressive microvascular renal disease in patients with chronic kidney disease. Endostatin levels in blood are also likely to increase in patients with other microvascular tissue injuries, including atherosclerosis, myocardial and brain ischemia. In ischemic stroke patients, high endostatin plasma levels predict a worse long-term clinical outcome. 

Click here for MSDS
Click here for PRODUCT LEAFLET
Click here for BIOMARKERS in CLINICAL NEPHROLOGY

Back to top